Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829662 | 0.94 | MRGPRX4 (0.44) | MAOBMRGPRX4 | |
| SCHEMBL14833307 | 0.92 | PTGER1 (0.41) | MRGPRX4 | |
| SCHEMBL14829619 | 0.91 | MAOB (0.43) | EGFRERBB2MAOBMRGPRX4NR4A2 | |
| SCHEMBL14830144 | 0.89 | MAOB (0.40) | EGFRERBB2MAOBMRGPRX4KDM4E | |
| SCHEMBL14833206 | 0.87 | EGFR (0.37) | EGFRERBB2MAOBMRGPRX4KDM4E | |
| SCHEMBL14829841 | 0.87 | EGFR (0.41) | EGFRERBB2MAOBMRGPRX4NR4A2 | |
| SCHEMBL14829632 | 0.87 | MAOB (0.46) | EGFRERBB2MAOBMRGPRX4KDM4E | |
| SCHEMBL14829691 | 0.86 | EGFR (0.39) | EGFRERBB2MAOBMRGPRX4KDM4E | |
| SCHEMBL14829849 | 0.86 | MRGPRX4 (0.44) | MAOBMRGPRX4 | |
| SCHEMBL14829792 | 0.86 | MRGPRX4 (0.39) | EGFRERBB2MAOBMRGPRX4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | claimed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | claimed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | disclosed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, RAF1 | EGFR 527/4885ERBB2 173/4885MAOB 183/4885 |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | EGFR 412/4885ERBB2 93/4885MAOB 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.